Palvella Therapeutics, Inc.
PVLA
$120.57
-$5.22-4.15%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 31.99% | 14.63% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 31.41% | 11.07% | |||
| Operating Income | -31.41% | -11.07% | |||
| Income Before Tax | -24.01% | -12.07% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -24.01% | -12.07% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -24.01% | -12.07% | |||
| EBIT | -31.41% | -11.07% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -12.52% | -4.43% | |||
| Normalized Basic EPS | -12.54% | -4.42% | |||
| EPS Diluted | -12.52% | -4.43% | |||
| Normalized Diluted EPS | -12.54% | -4.42% | |||
| Average Basic Shares Outstanding | 10.20% | 7.32% | |||
| Average Diluted Shares Outstanding | 10.20% | 7.32% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||